Citations

Clear

16280 citation(s) found for "Yu, David".

Outcomes of mechanical thrombectomy after recent cardiovascular procedures: a multicenter descriptive cohort
Ghozy, Sherief , Tolba, Hatem , Liu, Michael , Moreno, Diego Alejandro Ortega, Attar, Hatim, Khan, Muhib , Cancelliere, Nicole M., Tariq, Inshal, Kadirvel, Ramanathan , Lazzaro, Marc A., Pereira, Vitor Mendes, Kallmes, David F, Ghozy, Sherief , Dmytriw, Adam A. , Ortega-Moreno, Diego Alejandro , Cancelliere, Nicole M , Tariq, Inshal, Qureshi, Adnan Iqbal , Rabinstein, Alejandro A. , Kallmes, David F.

Mayo Clinic

Neurological Research | December 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1080/01616412.2025.2597833 | PMID 41320809 Get It

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
Croitoru, David , Brahimi, N. , Zabihi, Haleh , Seigel, Kyle , Shojaei, Delaram , McMullen, Eric , Alavi, Afsáneh , Archaempong, Lily , Drucker, Aaron M. , Weizman, Adam V. , Croitoru, Kenneth , Alavi, A , Croitoru, D , Sibbald, Cathryn , Inman, Robert Davies , Piguet, Vincent

Mayo Clinic

JEADV Clinical Practice | November 29, 2025 | Volume: 5 | Issue: 2 | Pages: 495-501

10.1002/jvc2.70227 Get It

ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary wound care centre. Methods A prospective observational study was conducted of patients referred for suspected PG between April 2021 and June 2023. Demographic, clinical and laboratory data, including biopsies and tissue cultures, were collected. Patients were categorised as having PG vs alternative diagnoses based on diagnostic criteria from Su, Maverakis and the PARACELSUS score. Results Of 60 patients (female, 51.7%; mean [SD] age 52.9 [14.0] years), 44 (73.3%) met at least one published diagnostic criterion for PG. The most common comorbidity was IBD (63.6%), followed by inflammatory arthritis (25.0%) and monoclonal gammopathy of undetermined significance (MGUS) (4.5%). Systemic corticosteroids were used by 40.9% of patients before referral, but steroid‐sparing agents and biologics were the primary treatments after consultation. Biologics and steroid‐sparing agents were associated with significant improvement in disease activity using the PGA score (average score decreased from 2.3 to 1.5, p < 0.005), with 40.9% achieving complete remission. Elevated serum inflammatory markers and faecal calprotectin were observed in PG patients but absent in non‐PG cases. Conclusions These prospective data support previously published rates of association between PG and systemic comorbidities. Steroid‐sparing anti‐neutrophilic and targeted therapies are effective steroid‐sparing strategies in managing PG. Small sample size and referral bias may limit generalisability.
Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study
Ferrante, M., Kaser, Arthur , Reinisch, Walter, Bragg, S. M., Lin, Zhantao, Lopes, Michelle Ugolini, Protić, Marijana , Jairath, Vipul , Sands, Bruce E , Bossuyt, Peter , Farraye, Francis A. , Hisamatsu, T., Kierkuś, Jarosław , Laharie, David , Siegmund, Britta , Hon, Kam‐Lun Ellis , Morris, Nathan , Danese, Silvio

Mayo Clinic

Zeitschrift für Gastroenterologie | November 27, 2025 | Volume: 62 | Issue: 05 | Pages: e481-e482

10.1055/s-0044-1786891 Get It

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
Garg, Amit , Strunk, Andrew , Midgette, Bria, Frasier, Kelly , Cohn, Erica, Aarts, Pim , Alhusayen, Raed , Bechara, Bitte Falk G., Brassard, Alain, Brown, Debra, Emtestam, Lennart , Benhadou, Farida , Fernández‐Peñas, Pablo , Gebauer, Kurt , Horváth, Barbara , Marzano, Angelo Valerio , Orenstein, Lauren A.V. , Pascual, J.C. , Piguet, Vincent, Resnik, Barry I., Roth, Gretchen M. , Straalen, Kelsey van, Ingram, John R , Ingram, J R , Garg, Amit, Cohn, Erica, Alavi, Afsáneh , Bettoli, Vincenzo , Chandran, Nisha Suyien , Choon, Siew Eng , Cohen, Steven R. , Daveluy, Steven , Mármol, V. del , Dellavalle, Robert Paul , Flowers, Richard Hal , Frew, John W. , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Hsiao, Jennifer L. , Jemec, Gregor B. E. , Lowes, Michelle A , Matusiak, Łukasz , Micheletti, Robert , Oon, Hazel H. , Ortega‐Loayza, Alex G. , Paek, So Yeon , Rosmarin, David M. , Sayed, Christopher J. , Silva, Dimitri Luz Felipe da , Thorlacius, Linnea , Tzellos, Thrasyvoulos , Zee, Hessel H. van der , Straalen, Kelsey R. van , Ingram, John R.

Mayo Clinic

JAMA Dermatology | November 26, 2025 | Volume: 162 | Issue: 1 | Pages: 72

10.1001/jamadermatol.2025.4652 | PMID 41296358 Get It

Importance Accurate classification and reliability in assessment for lesions of hidradenitis suppurativa (HS) by investigators is critical to the determination of responder status and to overall data quality in clinical trials. Objective To establish consensus-based morphological definitions of HS lesions and guidance statements that standardize investigator lesion assessments for implementation in clinical trials. Evidence Review Health professionals (primarily dermatologists) with expertise in the measurement of HS disease activity as well as novice raters completed a preliminary questionnaire in which participants were asked to assess images of HS lesions and provide qualitative feedback on their decision making. Based on this feedback, detailed morphologic definitions for lesions and guidance statements that standardize lesion assessments were formulated and presented for consensus voting in 2 electronic Delphi surveys. A virtual group discussion after round 1 supported participants in round 2 voting. Findings Response rates were 84.7% (50 of 59), 86.0% (43 of 50), and 90.9% (40 of 44) in the preliminary, electronic Delphi round 1, and electronic Delphi round 2 surveys, respectively. Morphological definitions for 11 lesion types achieved the prespecified 70% consensus threshold, with 9 definitions reaching at least 90% agreement. After 2 electronic Delphi rounds, 16 of 18 guidance statements achieved the prespecified consensus threshold, with 13 statements receiving endorsement from more than 80% of participants. Two guidance statements related to assessment of tunneled plaques with multiple openings and assessment of scalp lesions failed to reach consensus. Conclusions and Relevance Common morphologic definitions and guidance that standardize assessment of HS lesions can be implemented in clinical trial protocols and investigator trainings with the goals of improving accuracy and reliability of investigator ratings.
Patient Characteristics and Outcomes of Cardiac Rehabilitation Following Thoracic Aortic Dissection Surgery: A Multicenter Retrospective Study
Heybati, Kiyan , Ochal, Domenic, Poudel, Keshav , Zuberi, Eric , Deng, Jiawen , Dineen, Elizabeth H. , Brahmbhatt, Pavan M., Daugherty, David H., Farres, Sam, Landolfo, Kevin, Bonikowske, Amanda R. , Mergo, Patricia J. , Shapiro, Brian P. , Deng, J , Taylor, Bryan J. , Brahmbhatt, Pavan M., Landolfo, Kevin , Thomas, Randal J.

Mayo Clinic

Journal of Cardiopulmonary Rehabilitation and Prevention | November 26, 2025 | Volume: 46 | Issue: 1 | Pages: 50-57

10.1097/hcr.0000000000000982 | PMID 41294921 Get It

Purpose: Despite the 2022 American Heart Association/American College of Cardiology guidelines recommending cardiac rehabilitation (CR) after aortic dissection repair, both patient participation in CR and the associated clinical outcomes remain poorly understood. Methods: Adults (≥18 years of age) discharged alive following thoracic aortic dissection surgery across the Mayo Clinic Enterprise (January 2012 to November 2022), with follow-up until May 2024, were included (IRB #24-001141). Data were presented using summary statistics and logistic regression modeling. Results: A total of 186 patients were referred; 37% were female, and the median age was 64 (51, 73) years. Dissections were classified as type A (43%), type B (18%), or a combination, and 55% had residual dissection. Over half (53%) did not start CR, with older age (aOR = 0.97: 95% CI, 0.94 - 0.99; P = .003), family history of aortic dissections and/or aneurysms (aOR = 0.17: 95% CI, 0.04 - 0.54; P = .005), and tobacco use (aOR = 0.35: 95% CI, 0.13 - 0.91; P = .037) being associated with lower odds of enrollment. Of the 87 who enrolled, 34 did so at a Mayo Clinic facility. There were no complications, with no difference in adverse outcomes. Among those with evaluations at graduation from CR (n = 21), quality of life (Dartmouth index 16 [14, 19] vs 25 [22, 30]; P = .002) and 6-minute walk distance (488 [375, 531] vs 302 [235, 398] m; P = .001) improved. Conclusions: Following thoracic aortic dissection repair, CR significantly improved quality of life and functional capacity without adverse events. Further work is needed to improve enrollment and establish data-driven safety margins for exercise.
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Pl
Khanna, Dinesh , Spino, Cathie , Kleerup, Eric C., Harui, Airi, Ibrahim, Grace, Kim, Grace Hyun J. , Huang, Suiyuan, McLain, Richard, Tu, Yi‐Hsuan, Steen, Virginia , Weigt, S. Samuel , Lee, Joyce , Fischer, Aryeh , Scholand, Mary Beth , Gordon, Jessica , Dellaripa, Paul F. , Rosas, Iván O. , Hunninghake, Gary M. , Trojanowski, Marcin A. , Dematte, Jane E. , Hsu, Vivien , Domsic, Robyn T. , Raghu, Ganesh , Boente, R. , Roth, Michael D. , Investigators, the Scleroderma Lung Study III, Kim, Grace Hyun J , Nagaraja, Vivek , Silver, Richard M. , Gordon, Jessica K , Dellaripa, Paul F , Domsic, Robyn T , Mayes, Maureen D , Boente, Ryan D , Roth, Michael D , Khanna, Dinesh , Lee, Joyce S , Hunninghake, Gary M , Tashkin, Donald P. , Bernstein, Elana J. , Goldin, Jonathan , Nagaraja, Vivek , Simms, Robert W. , Mayes, Maureen D. , Investigators, the Scleroderma Lung Study III

Mayo Clinic

ACR Open Rheumatology | November 26, 2025 | Volume: 7 | Issue: 12 | Pages: No page available

10.1002/acr2.70126 | PMID 41294296 Get It

Objective Mycophenolate mofetil (MMF) can stabilize or improve lung function in systemic sclerosis–related interstitial lung disease (SSc‐ILD). We hypothesized that combining MMF with pirfenidone (PFD) would produce a significantly more rapid and/or greater improvement in lung function. Methods A randomized (1:1), double‐blind, placebo (PLA)‐controlled phase 2 trial was conducted in SSc‐ILD in which patients received PFD or PLA (801 mg three times daily) along with MMF (1,500 mg twice daily) for 18 months. The primary outcome was change in percent predicted forced vital capacity (FVC‐%). Linear mixed‐effects models assessed treatment differences in a modified intention‐to‐treat population. Results Only fifty‐one of 150 intended subjects (34%) were randomized (MMF+PLA, n = 24; MMF+PFD, n = 27). The FVC‐% improved from baseline to 18 months by 2.24 ± 1.35 (least‐squares mean [LSM] ± SEM) in the MMF+PLA group and 2.09 ± 1.28 in the MMF+PFD group (LSM treatment difference −0.14; P = 0.93). Median time to achieve a ≥3% improvement in FVC‐% was numerically faster in the MMF+PFD versus MMF+PLA group (12.3 vs 17.8 months, respectively), but the difference was not significant ( P = 0.33). For secondary outcomes, only the change over 18 months in the Patient‐Reported Outcomes Measurement Information System 29‐item physical function score, favoring MMF+PFD, reached statistical significance ( P = 0.04). Although other related patient‐reported outcomes (PROs) numerically favored the MMF+PFD group, as did quantitative high‐resolution computed tomography measures of ILD, the differences between groups did not reach statistical significance. Early withdrawals from study medication and adverse events of special interest were numerically greater with MMF+PFD (n = 8 vs 2 and n = 20 vs 7, respectively). Conclusion In this underpowered study, there was no statistically significant treatment difference in overall change in FVC‐% between groups. MMF+PFD was not as well tolerated as MMF+PLA.
Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine
Hosoya, Hitomi , Torres, Armando N. Bastidas , Fernandez‐Pol, Sebastian , Gubatan, John , Durán, George E. , Lohman, Claire , Wright, Charles V., Sahaf, Bita , Mackall, Crystal L. , Sidana, Surbhi , Khodadoust, Michael S. , Mikkilineni, Lekha, Duran, George E , Lohman, Claire , Mackall, Crystal , Miklos, David B , Sidana, Surbhi , Kurtz, David M , Khodadoust, Michael S , Hosoya, Hitomi , Najidh, Safa , Dong, Fei , Ehlinger, Zachary J. , Wright, Charles, Miklos, David B. , Kurtz, David M. , Mikkilineni, Lekha, Gubatan, John Mark

Mayo Clinic

Blood | November 25, 2025 | Volume: 147 | Issue: 11 | Pages: 1191-1198

10.1182/blood.2025031423 | PMID 41288531 Get It

Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for hematological malignancies, yet its potential to drive lymphomagenesis poses significant clinical concerns. In this study, we investigated the mechanisms underlying CAR T-cell–associated lymphomagenesis in the gastrointestinal (GI) tract on a single case, focusing specifically on the role of integrin α4β7 expression and a predisposing somatic SH2B3 mutation. We observed oligoclonal CAR T cells homing to, and clonally expanding in, the GI tract, with the dominant expanded clone harboring both a pathogenic SH2B3 mutation and a CAR transgene integration within a TFCP2 locus. The clonal CAR T cells subsequently transitioned beyond the GI tract into the peripheral blood, suggesting a potential pathway for systemic dissemination. We found clinical, histological, and molecular evidence demonstrating the efficacy of cyclosporine in reducing the expanded malignant clone and achieving durable clinical remission for more than a year. Our findings highlight the complex interplay between CAR T-cell therapy, preexisting genetic vulnerabilities, and the GI microenvironment, emphasizing the need for vigilant monitoring and tailored therapeutic strategies to address the risks associated with CAR T-cell lymphomagenesis.
Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience
Mattoon, Ellie Rose , Sullivan, David , Focosi, Daniele , Casadevall, Arturo , Mattoon, Ellie R , Sullivan, David J , Focosi, Daniele , Casadevall, Arturo , Joyner, Michael J. , Franchini, Massimo

Mayo Clinic

Clinical Microbiology Reviews | November 25, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1128/cmr.00060-24 | PMID 41288364 Get It

SUMMARY COVID-19 convalescent plasma (CCP) was the first specific therapy deployed for treating SARS-CoV-2 infection. CCP was successfully deployed in both resource-poor and resource-rich countries, establishing that convalescent plasma (CP) is a feasible option for combating the next pandemic. CCP reduced mortality and progression to hospitalization when used early in the disease with high-titer units. This knowledge was gained from a worldwide effort that included more than 50 countries. However, the deployment of CCP was haphazard and varied among countries. Clinical studies suffered from a lack of standardization regarding study design, CCP antibody dosing, timing of administration, and participant disease severity. Unfortunately, the hard-won knowledge from the serum therapy era in the early 20th century, which indicated that effective antibody therapy requires early use in the disease with a sufficient antibody dose, was largely forgotten. Many studies tested CCP late in the disease or without sufficient antibody titer and thus reported negative findings. Trial heterogeneity made it difficult to combine the results of studies. However, despite tremendous heterogeneity in study design and participant populations, meta-analysis revealed strong signals of efficacy when given early with high antiviral-specific antibody levels. When the next pandemic occurs, humanity is likely to resort to CP again. To avoid another chaotic rollout, planning for CP use should begin well before that emergency arrives and must involve both physician education on the principles of antibody therapy and clinical trial designs that test its efficacy in optimal conditions, which include early use with sufficient antibody doses.
Establishing a consensus definition of VEXAS flare for clinical research
Weeks, Lachelle D. , Hammond, Danielle , Savic, Sinisa , Heiblig, Maël , Chowdhury, Onima , Mékinian, A. , Ramchandren, Radhakrishnan , Georgin‐Lavialle, Sophie , Ferrada, Marcela A. , Buckley, Sarah , Harder, Bryan , Beck, David B. , Mékinian, Arsène , Gurnari, Carmelo , Ramchandren, Radhakrishnan , Georgin-Lavialle, Sophie , Ferrada, Marcela A , Buckley, Sarah A , Harder, Bryan G , Beck, David B , Koster, Matthew J , Weeks, Lachelle Dawn , Hammond, Danielle , Heiblig, Mael , Savic, Sinisa , Gurnari, Carmelo , Koster, Matthew J.

Mayo Clinic

Rheumatology | November 25, 2025 | Volume: 65 | Issue: 2 | Pages: No page available

10.1093/rheumatology/keaf624 | PMID 41289141 Get It

Abstract Objective VEXAS syndrome is a severe systemic haemato-inflammatory disease with heterogeneous clinical presentations. Most patients experience recurrent inflammatory flares despite anti-inflammatory therapy. The lack of accepted definitions of flare in these patients is preventing development of disease activity tools that are essential for conducting clinical trials. We aimed to develop a consensus definition of a VEXAS flare for use in clinical trials. Methods A nine-member international expert advisory committee established a consensus definition of VEXAS flare using modified Delphi methodology. Clinical inflammatory manifestations of VEXAS syndrome were identified through a systematic literature review. Committee members developed a conceptual framework for flare definition, proposed revisions and voted on changes until consensus (≥75% concurrence) was reached. Results Consensus defined VEXAS flare as active inflammatory manifestation(s) of VEXAS syndrome requiring escalation in glucocorticoid therapy. Three flare categories were established: (i) recurrence of a prior documented VEXAS manifestation; (ii) development of a new VEXAS-defining inflammatory manifestation; or (iii) emergence of a new inflammatory manifestation not meeting criteria for A or B. The panel endorsed an independent adjudication committee to assess Category C flares in clinical trials. Conclusions This study proposes a standardized definition of VEXAS flare, providing uniform criteria for identifying VEXAS disease activity. Future research will evaluate its performance in clinical trials.
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Cook, Eleanor , Rotz, Seth J. , Blacken, Robyn, Johnson, Darren, Alonso, Priscila Badia , French, Karis, Kent, Georgia , Huber, John , Hammoud, Miza Salim , Parker, Loretta , Kusnier, Katilyn , Lehmann, Leslie , Kapadia, Malika, Khera, Nandita , Nishitani, Miki , Craddock, John , Juckett, Mark, Maier, Steffani, O'Mathúna, Dónal, Phelan, Rachel , Young, Kylan, Jodele, Sonata , Snyder, Alana J. , Sampson, Megan , Dandoy, Christopher E. , Fitch, Taylor Jennelle , Badia, Priscila , Huber, John , Hammoud, Miza Salim , Myers, Kasiani , Craddock, John A , Jodele, Sonata , Schoettler, Michelle L , Sampson, Megan , Dandoy, Christopher E , Auletta, Jeffery J. , Bidgoli, Alan , French, Karis, Hartley, David , Maier, Steffani T. , O'Mathúna, Dónal, Nelson, Adam S. , Phelan, Rachel , Young, Kylan

Mayo Clinic

Pediatric Blood & Cancer | November 24, 2025 | Volume: 73 | Issue: 3 | Pages: No page available

10.1002/pbc.70001 | PMID 41277289 Get It

ABSTRACT Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.